Cost differences among treatment options for patients with refractory myeloma previously treated with high-dose chemotherapy and autologous stem-cell transplantation: An analysis from the U.S. and Swiss perspectives.
P. R. Blank
No relevant relationships to disclose
R. Levin
No relevant relationships to disclose
B. C. Pestalozzi
No relevant relationships to disclose
T. D. Szucs
No relevant relationships to disclose